Status:
COMPLETED
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
Lead Sponsor:
Ascendis Pharma A/S
Conditions:
Achondroplasia
Eligibility:
All Genders
Up to 8 years
Brief Summary
This is a long-term, multi-center, longitudinal, observational study in children with achondroplasia (ACH). The aim is to study height velocity and comorbidities in children with ACH. This is a natura...
Eligibility Criteria
Inclusion
- Legally authorized representative is willing and able to provide written, signed informed consent (with a written assent from the child when appropriate per local requirements)
- Willing and able to comply with study protocol per investigator judgement
- Clinical diagnosis of achondroplasia (confirmed by the investigator)
- Age between 0 to 8 years old at enrollment
- Able to stand without assistance (if the child is 24 months or older)
Exclusion
- Have received chronic treatment (\> 3 months) of human growth hormone (hGH) or other medicinal products intended to affect stature or body proportionality at any time
- Have received any dose of medicinal products intended to affect stature or body proportionality within the previous 6 months of screening
- Have received any investigational medicinal product or device intended to affect stature or body proportionality at any time
- History or presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones
- History of any bone-related surgery that affects growth potential of long bones, such as orthopedic reconstructive surgery and osteotomy (foramen magnum decompression, and laminectomy with full recovery are allowed with minimum of 6 months of bone healing. Limb-lengthening with full recovery is allowed with a minimum of 12 months of bone healing.)
- Have forms of skeletal dysplasias other than achondroplasia or medical conditions that result in short stature or abnormal bone growth \[such as severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), hypochondroplasia, growth hormone deficiency, Turner syndrome, pseudoachondroplasia. uncontrolled hypothyroidism, uncontrolled diabetes mellitus, autoimmune disease requiring corticosteroid therapy, inflammatory bowel disease, and chronic renal insufficiency\]
- History or presence of malignant disease, other than basal cell epithelioma/carcinoma or completely resected squamous skin cancer with no recurrence for 12 months per medical records
Key Trial Info
Start Date :
June 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 12 2024
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT03875534
Start Date
June 19 2019
End Date
January 12 2024
Last Update
March 19 2024
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Ascendis Pharma Investigational Site
Little Rock, Arkansas, United States, 72211
2
Ascendis Pharma Investigational Site
Oakland, California, United States, 94609
3
Ascendis Pharma Investigational Site
Aurora, Colorado, United States, 80045
4
Ascendis Pharma Investigational Site
Wilmington, Delaware, United States, 19803